The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ZBIO | +222.07% | N/A | N/A | +114% |
| S&P | +14.18% | +88.25% | +13.47% | +22% |
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.01M | 69.4% |
| Gross Margin | 99.77% | 0.0% |
| Market Cap | $934.85M | 38.8% |
| Market Cap / Employee | $7.19M | 0.0% |
| Employees | 130 | 0.0% |
| Net Income | -$51.50M | -33.4% |
| EBITDA | -$47.57M | -16.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $115.57M | -67.9% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.18M | 0.0% |
| Short Term Debt | $0.62M | 60.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -52.35% | 0.0% |
| Return On Invested Capital | -126.07% | 37.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$41.13M | -32.4% |
| Operating Free Cash Flow | -$41.13M | -32.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.39 | 1.06 | 1.43 | 3.90 | 98.26% |
| Price to Sales | 68.46 | 22.02 | 27.05 | 62.40 | - |
| Price to Tangible Book Value | 1.39 | 1.06 | 1.43 | 3.90 | 98.26% |
| Enterprise Value to EBITDA | 0.14 | -0.51 | -2.42 | -13.58 | 73.46% |
| Return on Equity | -115.5% | -88.4% | -68.3% | - | |
| Total Debt | $1.00M | $1.23M | $1.01M | $0.80M | 107.81% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
